# Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

> **NCT00738829** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 45 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00738829
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738829, "Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00738829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*